{
    "pmcid": "8043454",
    "qa_pairs": {
        "How were the nanobody repertoires targeting the SARS-CoV-2 Spike protein developed in the study?": [
            "By immunizing llamas with Spike subunits and using advanced screening and sequencing techniques.",
            "By synthesizing nanobodies in vitro using recombinant DNA technology.",
            "By isolating nanobodies from human plasma samples of COVID-19 survivors.",
            "By engineering nanobodies based on computer-aided design and structural modeling."
        ],
        "What is a key advantage of nanobodies over traditional monoclonal antibodies in targeting the SARS-CoV-2 Spike protein?": [
            "Nanobodies can access epitopes that are inaccessible to conventional antibodies due to their small size.",
            "Nanobodies have a higher molecular weight, which allows for better binding to the Spike protein.",
            "Nanobodies are less stable than traditional antibodies, making them more adaptable to mutations.",
            "Nanobodies require more complex engineering processes compared to traditional antibodies."
        ],
        "What method was used to analyze the binding affinity of nanobodies to the SARS-CoV-2 Spike protein?": [
            "Surface plasmon resonance (SPR) analysis.",
            "Enzyme-linked immunosorbent assay (ELISA).",
            "Western blotting.",
            "Flow cytometry."
        ],
        "What potential therapeutic application is highlighted for nanobodies in the fight against COVID-19?": [
            "Their ability to be delivered directly to the lungs and resistance to escape variants.",
            "Their use as a vaccine adjuvant to enhance immune response.",
            "Their role in diagnosing COVID-19 through rapid antigen tests.",
            "Their application in gene therapy to modify host cell receptors."
        ],
        "What strategy was employed to enhance the resistance of nanobodies to escape variants of SARS-CoV-2?": [
            "Targeting diverse epitopes and using combinatorial nanobody mixtures.",
            "Increasing the size of nanobodies to cover more surface area on the Spike protein.",
            "Focusing solely on the receptor-binding domain (RBD) of the Spike protein.",
            "Utilizing only monomeric forms of nanobodies for increased specificity."
        ]
    }
}